GSK

Today marks another incredible milestone as Liberia and Benin introduce the world's first malaria vaccine, RTS,S, into their routine immunisation programmes. In parallel, our partnership with Last Mile Health is funding a programme for the integration of malaria vaccinations into routine vaccination protocols in Liberia, ensuring that even the most remote communities receive this life-saving intervention. By engaging community health workers, Last Mile Health are reaching the children who need it the most. We’re proud to be working together with Last Mile Health, whose impactful work brings essential healthcare and support to underserved communities. #WorldMalariaDay #ZeroMalaria #WorldImmunisationWeek

From developing the world’s first malaria vaccine to investigating the potential of novel antimalarials to tackling increasing drug resistance and exploring the next-generation of malaria vaccines, our global health R&D is helping #ChangeTheTrajectory of malaria for people and communities in lower income countries.       👉 Scroll across to learn more about how our R&D is helping us get ahead of malaria.     #WorldMalariaDay #ZeroMalaria 

It’s critical that we prioritise preventative healthcare and focus on a life course approach to #vaccination, during #WorldImmunisationWeek and beyond. Let’s work to make adult immunisation the standard of care to support healthy ageing. #WIW2024 Find out more 👇

Including the people most impacted by a particular disease in clinical trials is crucial to advancing our understanding of new medicines and vaccines. It's also a foundational step to achieving health equity. For the past two years, 100% of our Phase III clinical trials have had diversity plans in place before enrolment has started to reflect the people most impacted by a particular disease, considering factors such as age, sex, race, and ethnicity. This year, we have set an ambitious target to enrol the communities represented in these plans into our trials so that our data better represents real-world outcomes for patients. But we can't do this alone. Building trust and collaborating with others is essential, which is why we're committed to working with regulators, patients, academia, other biopharma companies, and the broader healthcare ecosystem to positively impact patients' lives and get ahead of disease together. #AheadTogether #InclusiveResearch

#News for #Investors and #Media: Today, we announced that our application for a potential expanded indication for our immuno-oncology therapy has been accepted by the FDA with Priority Review status. Learn more here: https://gsk.to/3xUd3gg

Last year, we embarked on a new five-year, £15m investment with our longstanding partner Save the Children UK to reduce the number of zero dose children, those who have never received a routine vaccination, in Ethiopia and Nigeria. Thanks to our partnership, today, we are thrilled that Save the Children is launching its ‘Immunisation Accelerator'. This new $1 million initiative is open for applications from innovative partners in Ethiopia and Nigeria who are passionate about the vision of a world where no child suffers from a vaccine-preventable disease. In this latest Behind the Science article, Dr Tewodros Gebremichael, Save the Children’s Regional Child Survival Technical Advisor, explains more about the Accelerator, what innovation partners Save the Children is looking for and why they’ll be key in helping tackle the long-standing barriers to children receiving vaccinations: https://gsk.to/3vWav0u #WorldImmunisationWeek

A #HealthEquity gap exists between those who can access healthcare, and those who remain underserved due to preventable factors. This affects not only patients but also burdens the economy and the healthcare services. Answer the question below and read our article to check if you were correct: https://gsk.to/3vODvqX

For #investors and #media: Today we have announced new positive long-term follow-up trial data in shingles and phase III data in uncomplicated urogenital gonorrhoea (GC). Find out more: https://www.gsk.com/en-gb/

#News for #Media and #Investors: Today, we announced that the Biologics License Application for our vaccine candidate has been accepted by the FDA. Find out more: https://gsk.to/4d0hvtA

Everyone should have access to the medicines and vaccines they need to achieve optimal health regardless of who they are or where they come from. However, the world is far from perfect, and a health equity gap exists between those who can access healthcare, and those who remain underserved. This gap not only stops many patients from getting the treatment they need, but also places huge financial burden on healthcare services and economies. Read our article on how healthcare companies, like GSK, are working with partners and communities to close health equity gaps that exist within countries and between them – and why doing so benefits all of us: https://gsk.to/3xDJ2AT